ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Pharmacological evolution of natural product-based and chemically engineered autophagy-modulating strategies in neurodegenerative diseases: a bibliometric mapping analysis (2006-2025).
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological modulation of autophagy has become an important neuropharmacological strategy for neurodegenerative diseases. However, the comparative development of natural product-based and chemically engineered autophagy-modulating strategies has not been systematically mapped. This study aimed to characterize the global research landscape, pharmacological strategy distribution, mechanistic hotspots, and translational development of autophagy modulation in neurodegenerative diseases from 2006 to 2025. Publications were retrieved from the Web of Science Core Collection and analyzed using VOSviewer, CiteSpace, bibliometrix, and SCImago Graphica. A total of 4344 records were classified at the publication level into four mutually exclusive categories according to a predefined classification dictionary, with assignments independently reviewed by two investigators and discrepancies resolved by consensus. Chemically designed, semisynthetic, or target-oriented approaches are collectively referred to as chemically engineered strategies in this study. Research output increased markedly after 2014. China contributed the largest number of publications (n = 1678, 38.6%), followed by the United States (n = 627, 14.4%). Chemically engineered strategies constituted the largest analytical category (n = 2255, 51.91%), followed by natural product-based strategies (n = 1058, 24.36%), mechanism-focused or unresolved studies (n = 920, 21.18%), and overlapping strategies (n = 111, 2.56%). Natural product-based strategies showed an overall increase in relative contribution after 2014. Recent hotspots were organized around selective autophagy, particularly mitophagy; autophagic maturation and lysosomal quality control; and crosstalk with stress and cell death pathways such as ferroptosis. The field is shifting from generalized autophagy induction toward mechanism-defined, increasingly selective, and pharmacologically testable interventions. Future studies should integrate target engagement, concentration-response relationships, flux-resolved assays, brain exposure, cargo selectivity, and long-term safety assessment to improve translational credibility.
Indexed as
Identifiers
42543391What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.